Skip to main content
. 2021 Dec 11;3(1):28–41.e8. doi: 10.1016/j.medj.2021.12.002

Figure 2.

Figure 2

Cohort analysis to compare the incidence rates of symptomatic infection after vaccination with mRNA-1273 versus BNT162b2

(A) The secondary analysis was conducted as a retrospective cohort study. After matching on the basis of demographic and clinical features, we compared the incidence rates of symptomatic infection after full vaccination with mRNA-1273 versus after full vaccination with BNT162b2.

(B) Incidence rate ratios (IRRs) of symptomatic infection for unmatched (top), matched per protocol (PP) (middle), and matched intention-to-treat (ITT) (bottom) analyses. IRRs are shown for days 1–10 after the first dose (baseline estimate), the entire study duration (December 1, 2020 through September 22, 2021), the early epoch (December 1, 2020 through May 31, 2021), and the late epoch (July 1, 2021 through September 22, 2021). The x axis is log-transformed such that, for example, IRRs of 0.5 and 2 are equidistant from the null hypothesis IRR of 1. Error bars represent 95% confidence intervals.